FabRx announces launch of M3DIMAKER
FabRx Ltd., the innovative pharmaceutical biotechnology spin-out from University College London (UCL) pioneering 3D printing of pharmaceuticals, has released the first pharmaceutical 3D printer M3DIMAKER for the manufacture of personalised medicines. FabRx is thrilled to announce that their cutting edge alternating nozzle 3D printing system, which has been tested in hospitals, pharmacies and research institutes around the world, has now been launched onto the market.
Continue reading “FabRx announces launch of M3DIMAKER, first pharmaceutical 3D printer for manufacturing personalised medicines”
FabRx starts crowdfunding campaign for personalised medicine 3D Printer
The new printer and software produces personalised medicines adapted for individual patients’ needs
FabRx is the first pharmaceutical company to work and act on the dream of personalised medicines using 3D printing technology. FabRx, in partnership with The Magic Candy Factory are working together to adapt a confectionary 3D printer to prepare medicines that are ideal for children. FabRx announces the starting of a crowdfunding campaign to raise money and create awareness about this innovative technology on Wednesday 6th December. You can find more information about the Kickstarter campaign in the following link:
The new printer allows the tailored manufacturing of medicines, including:
• precise dose medication (personalised doses)
• the combination of more than one drug (Polypill)
• a range of formulations (tablets, capsules, chewable formulations) and
• preparing these medicines on-demand in hospitals or pharmacies Continue reading “FabRx starts crowdfunding campaign for personalised medicine 3D Printer”
3D Printing of medicines, current and future challenges – Presented by Alvaro Goyanes, FabRx at The 3D Medicine & Pharmaceutical Printing Conference which will take place on Feb 01, 2017 at MECC Maastricht in The Netherlands. Continue reading “3D Printing of medicines, current and future challenges – Presented by Alvaro Goyanes, FabRx”
3-dimensional printing (3DP) of medicines is becoming an increasingly popular trend, especially since the first 3D printed medicine (Spritam®) was approved by the FDA in August 2015.
Researchers from University College London – School of Pharmacy and FabRx Ltd. have recently published a paper in International Journal of Pharmaceutics in which they show, for the first time, the fabrication of oral tablets by stereolithography. Continue reading “Researchers reveal process of 3-dimensional printing oral tablets by stereolithography”